Latham & Watkins Advises Boston Scientific in Acquisition of Valencia Technologies Corporation

Boston Scientific Corporation (NYSE: BSX) has announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB). Boston Scientific expects to complete the acquisition in the first half of 2026, subject to customary closing conditions.

Latham & Watkins LLP represents Boston Scientific in the transaction with a corporate deal team led by Boston partner Julie Scallen and Boston counsel Cory Lewis, with associates Sue Yeon Kim, Cherrie Wang, and Emma Bowler. Advice was also provided on tax matters by Washington, D.C. partners Nicholas DeNovio and Abigail Friedman; on intellectual property matters by New York counsel Eliot Choy, with associate Arun Mohan; on litigation matters by Boston partner Nathan Sandals, with assistance from Zach Edelman; on healthcare matters by Bay Area partners Heather Deixler and Betty Pang, Washington, D.C. counsel Chad Jennings, and associate Zac Alpert; and on employment matters by Washington, D.C. partner Nikhil Kumar and New York counsel Sandra Benjamin, with associate Christina Schrantz.